Corrigendum to Recombinant human soluble thrombomodulin in severe sepsis: A systematic review and meta-analysis. [J Thromb Haemost (2015)]; DOI: 10.1111/jth.12841;Recombinant human soluble thrombomodulin in severe sepsis: A systematic review and meta-analysis

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 4, 2015, Pages 508-519

  Yamakawa, K ^a   Aihara, M ^b   Ogura, H ^a   Yuhara, H ^c   Hamasaki, T ^d   Shimazu, T ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

disseminated intravascular coagulation; Anticoagulant drugs; Meta analysis; Sepsis; Thrombomodulin

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN; RECOMBINANT THROMBOMODULIN; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; RECOMBINANT PROTEIN; THBD PROTEIN, HUMAN; THROMBOMODULIN;

ARTICLE; BLEEDING; CASE CONTROL STUDY; CATHETER OCCLUSION; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EFFECT SIZE; HUMAN; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEPSIS; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DISSEMINATED INTRAVASCULAR COAGULATION; ODDS RATIO; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ANTICOAGULANTS; CHI-SQUARE DISTRIBUTION; DISSEMINATED INTRAVASCULAR COAGULATION; HEMORRHAGE; HUMANS; ODDS RATIO; RECOMBINANT PROTEINS; RISK FACTORS; SEPSIS; SEVERITY OF ILLNESS INDEX; THROMBOMODULIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926076079     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12941     Document Type: Erratum

References (45)

1. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36: 222-31.
2. Miller RR 3rd, Dong L, Nelson NC, Brown SM, Kuttler KG, Probst DR, Allen TL, Clemmer TP. Multicenter implementation of a severe sepsis and septic shock treatment bundle. Am J Respir Crit Care Med 2013; 188: 77-82.
3. Ferrer R1, Artigas A, Levy MM, Blanco J, González-Díaz G, Garnacho-Montero J, Ibáñez J, Palencia E, Quintana M, de la Torre-Prados MV; Edusepsis Study Group. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008; 299: 2294-303.
4. Opal SM, Cross AS. Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 1999; 13: 285-97, vii.
5. Dellinger RP. Severe sepsis trials: why have they failed? Minerva Anestesiol 1999; 65: 340-5.
6. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM; KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-78.
7. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Artigas A, Percell SR, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-47.
8. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30: 536-55.
9. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.
10. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
11. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055-64.
12. Levi M, van der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol 2013; 79: 294-8.
13. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31-41.
14. Aikawa N, Shimazaki S, Yamamoto Y, Saito H, Maruyama I, Ohno R, Hirayama A, Aoki Y, Aoki N. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 2011; 35: 349-54.
15. Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, Tasaki O, Ogura H, Kuwagata Y, Hamasaki T, Shimazu T. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 2011; 15: R123.
16. Ogawa Y, Yamakawa K, Ogura H, Kiguchi T, Mohri T, Nakamori Y, Kuwagata Y, Shimazu T, Hamasaki T, Fujimi S. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 2012; 72: 1150-7.
17. Wada H, Okamoto K, Iba T, Kushimoto S, Kawasugi K, Gando S, Madoiwa S, Uchiyama T, Mayumi T, Seki Y. Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan". Thromb Res 2014; 134: 924-5.
18. Di Nisio M, Baudo F, Cosmi B, D'Angelo A, De Gasperi A, Malato A, Schiavoni M, Squizzato A. Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2012; 129: e177-84.
19. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, Kim HK, Nielsen JD, Dempfle C-E, Levi M, Toh CH. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; 11: 761-7.
20. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-94.
21. Aihara M, Mihara H, Murayama T, Aihara T, Fukuda S. GRADE System for Clinical Practice Guideline-Therapeutic Intervention. Hirosaki: Toppan Media, 2010 [in Japanese].
22. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, Jang BH, Son HJ. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013; 66: 408-14.
23. Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J, Puigserver JV, Blanzaco DU, Esmon CT, Parrillo JE, Guzzi L, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; 41: 2069-79.
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
25. Takahashi H, Isotani E, Usizawa H, Wakabayashi M, Shoko T, Aiboshi J, Kaji M, Otomo Y. Effect of recombinant thrombomodulin for sepsis-induced disseminated intravascular coagulation. ICU & CCU 2011; 35: 581-4 [in Japanese].
26. Ohryorji T, Kakihana Y, Yasuda T, Kiyonaga Y, Kuroki C, Nakahara M, Imabayashi T, Kanmura Y. Efficacy of combination of recombinant human soluble thrombomodulin with conventional therapy in disseminated intravascular coagulation. J Jpn Soc Intensive Care Med 2011; 18: 583-90 [in Japanese].
27. Yada N, Nishio K, Seki T, Fukushima H, Urizono Y, Hata M, Okuchi K. Therapeutic effect of recombinant thrombomodulin on the hemostatic and inflammatory response in patients with septic DIC. Nihon Kyukyu Igakukai Zasshi 2011; 22: 749-57 [in Japanese].
28. Kudo D, Shinozawa Y, Yamanouchi S, Endo T, Sato T, Furukawa H, Nomura R, Kushimoto S. Treatment effect of thrombomodulin-α on septic disseminated intravascular coagulation (DIC): a historical control study. J Jpn Soc Intensive Care Med 2012; 19: 359-66 [in Japanese].
29. Umegaki T, Nishi K, Hatano K, Okamoto A, Hamano N, Yamazaki E, Sakamoto S, Shingu K. Effects of recombinant human soluble thrombomodulin and Danaparoid sodium for sepsis-induced disseminated intravascular coagulation. J Jpn Soc Intensive Care Med 2012; 19: 603-8 [in Japanese].
30. Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T, Nakamori Y, Inoue Y, Kuwagata Y, Tanaka H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 2013; 39: 644-52.
31. Kato T, Sakai T, Kato M, Hagihara M, Hasegawa T, Matsuura K, Nakagawa T. Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J 2013; 11: 3.
32. Sawano H, Shigemitsu K, Yoshinaga Y, Tsuruoka A, Natsukawa T, Hayashi Y, Kai T. Combined therapy with antithrombin and recombinant human soluble thrombomodulin in patients with severe sepsis and disseminated intravascular coagulation. Nihon Kyukyu Igakukai Zasshi 2013; 24: 119-31 [in Japanese].
33. Yamato M, Minematsu Y, Fujii J, Mori K, Minato T, Miyagawa S, Fujimura R, Morikage N, Arata Y, Nakano C, Wada A, Ito T. Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial. Ther Apher Dial 2013; 17: 472-6.
34. Sha K, Sakamoto T, Takeda M, Horiuchi T, Kurita N, Yamaguchi A, Nagahata T. The efficacy of thrombomodulin treatment with severe infection which induced disseminated intravascular coagulation. ICU & CCU 2013; 37: 137-41 [in Japanese].
35. Williams SC. After Xigris, researchers look to new targets to combat sepsis. Nat Med 2012; 18: 1001.
36. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-52.
37. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.
38. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost 2003; 1: 1515-24.
39. Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011; 9(Suppl 1): 168-73.
40. Li YH, Kuo CH, Shi GY, Wu HL. The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci 2012; 19: 34.
41. Okamoto T, Tanigami H, Suzuki K, Shimaoka M. Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis. Crit Care Res Pract 2012; 2012: 614545.
42. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL. Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003; 29: 894-903.
43. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM; KyberSept Investigators. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285-92.
44. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13: 34-45.
45. Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, Kuroda T, Sakata Y. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res 2013; 131: 436-43.